Abstract
Insights into the pathogenesis of type 2 diabetes has led to increasing therapeutic targets for intervention, and improvements in peptide delivery technology have lead to non-injection methods of insulin delivery. This article reviews new drugs which are likely to become available for use by people with diabetes over the coming year.
MeSH terms
-
Adenosine Deaminase Inhibitors
-
Administration, Inhalation
-
Amyloid
-
Cannabinoid Receptor Antagonists
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Dipeptidyl Peptidase 4
-
Dipeptidyl-Peptidase IV Inhibitors
-
Forecasting
-
Glucagon-Like Peptide 1 / antagonists & inhibitors
-
Glycoproteins / antagonists & inhibitors
-
Humans
-
Hypoglycemic Agents / therapeutic use*
-
Insulin / administration & dosage
-
Islet Amyloid Polypeptide
-
Technology, Pharmaceutical / trends*
Substances
-
Adenosine Deaminase Inhibitors
-
Amyloid
-
Cannabinoid Receptor Antagonists
-
Dipeptidyl-Peptidase IV Inhibitors
-
Glycoproteins
-
Hypoglycemic Agents
-
Insulin
-
Islet Amyloid Polypeptide
-
Glucagon-Like Peptide 1
-
DPP4 protein, human
-
Dipeptidyl Peptidase 4